Tag: Axl

ONO-7475 is a Selective and Orally Active AXL/Mer Inhibitor

EGFR tyrosine kinase inhibitors (EGFR-TKIs) are efficient for the treatment of non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, most EGFR-positive NSCLC patients exhibit resistance to EGFR-TKIs after sometimes. The 3rd generation EGFR-TKI Osimertinib shows efficacy for overcoming EGFR T790M mutation-positive NSCLC. Anexelekto (AXL) belongs to the TAM...

BPI-9016M is an Orally Active and Selective Dual c-Met/AXL Inhibitor

c-Met is a membrane-spanning receptor tyrosine kinase. It has a high affinity for binding to hepatocyte growth factor (HGF). As we all know, HGF/c-Met signaling often involves activation of its downstream pathways. High-level Met gene amplification, mutation or protein overexpression can lead to aberrant activation of the HGF/c-Met pathway. In...

RU-302, a pan-TAM Inhibitor, Blocks Gas6-Inducible TAM Activation and Tumorigenicity

The TAM receptors (Tyro-3, Axl, and Mertk) are a family of three homologous types I receptor tyrosine kinases (RTKs). They play an indispensable role in homeostasis and the resolution of inflammation under physiological conditions. Pathophysiologically, TAMs frequently overexpressed in a wide variety of human cancers that are associated with...